Swiss National Bank Portfolio holdings
The Swiss National Bank (SNB), founded in 1907 and headquartered in Zurich with an office in Bern, is Switzerland’s central bank, responsible for conducting monetary policy, issuing the Swiss franc, and ensuring price stability, while uniquely managing a massive investment portfolio. Unlike most central banks, the SNB is a joint-stock company with shares traded on the SIX Swiss Exchange, owned roughly 55% by public entities like cantons and 45% by private investors, yet it operates independently under federal oversight. It holds over $800 billion in foreign currency reserves as of late 2024—invested in global equities, bonds, and gold—to manage the franc’s value, famously intervening in markets to prevent excessive appreciation, as seen with the 2015 abandonment of the euro peg. Led by Chairman Thomas Jordan until his planned exit in September 2024, the SNB balances its dual role as a monetary authority and a significant global investor, influencing both Swiss and international financial stability.
Top Buys
| 1 |
Broadcom
AVGO
|
+$67.3M |
| 2 |
Veralto
VLTO
|
+$60.2M |
| 3 |
Newmont
NEM
|
+$43.4M |
| 4 |
Vertiv
VRT
|
+$19.4M |
| 5 |
Webster Financial
WBS
|
+$17.3M |
Top Sells
| 1 |
Apple
AAPL
|
+$328M |
| 2 |
Microsoft
MSFT
|
+$244M |
| 3 |
ATVI
Activision Blizzard Inc.
ATVI
|
+$237M |
| 4 |
VMW
VMware, Inc
VMW
|
+$130M |
| 5 |
NVIDIA
NVDA
|
+$109M |
Sector Composition
| 1 | Technology | 30.91% |
| 2 | Healthcare | 12.91% |
| 3 | Consumer Discretionary | 12.16% |
| 4 | Industrials | 9.36% |
| 5 | Communication Services | 8.58% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1576
Gulfport Energy Corp
GPOR
$3.06B
| $3.18M | ﹤0.01% |
23,900
-500
| -2% | -$66.6K |
|
1577
Upbound Group
UPBD
$1.45B
| $3.18M | ﹤0.01% |
93,700
-10,800
| -10% | -$367K |
|
1578
PROS Holdings
PRO
$699M
| $3.18M | ﹤0.01% |
82,000
-9,200
| -10% | -$357K |
|
1579
Catalyst Pharmaceutical
CPRX
$2.44B
| $3.18M | ﹤0.01% |
189,100
-33,400
| -15% | -$561K |
|
1580
Arcellx
ACLX
$4.23B
| $3.17M | ﹤0.01% |
57,200
-6,100
| -10% | -$339K |
|
1581
Vericel Corp
VCEL
$1.62B
| $3.17M | ﹤0.01% |
89,100
-10,200
| -10% | -$363K |
|
1582
JELD-WEN Holding
JELD
$537M
| $3.17M | ﹤0.01% |
167,900
-18,900
| -10% | -$357K |
|
1583
Stewart Information Services
STC
$2.09B
| $3.17M | ﹤0.01% |
53,900
-5,800
| -10% | -$341K |
|
1584
Ironwood Pharmaceuticals
IRWD
$213M
| $3.17M | ﹤0.01% |
276,700
-30,600
| -10% | -$350K |
|
1585
La-Z-Boy
LZB
$1.39B
| $3.13M | ﹤0.01% |
84,900
-10,300
| -11% | -$380K |
|
|
NVEE
1586
DELISTED
NV5 Global
NVEE
| $3.13M | ﹤0.01% |
112,800
-11,600
| -9% | -$322K |
|
1587
Newmark Group
NMRK
$3.41B
| $3.13M | ﹤0.01% |
285,307
-34,700
| -11% | -$380K |
|
|
VGR
1588
DELISTED
Vector Group Ltd.
VGR
| $3.12M | ﹤0.01% |
276,573
-32,000
| -10% | -$361K |
|
1589
NETSCOUT
NTCT
$1.8B
| $3.12M | ﹤0.01% |
142,128
-14,500
| -9% | -$318K |
|
1590
Viking Therapeutics
VKTX
$2.79B
| $3.12M | ﹤0.01% |
167,600
-29,900
| -15% | -$556K |
|
1591
First Commonwealth Financial
FCF
$1.84B
| $3.12M | ﹤0.01% |
201,800
-24,400
| -11% | -$377K |
|
1592
Supernus Pharmaceuticals
SUPN
$2.55B
| $3.11M | ﹤0.01% |
107,600
-12,100
| -10% | -$350K |
|
|
ARI
1593
Apollo Commercial Real Estate
ARI
$1.51B
| $3.11M | ﹤0.01% |
264,639
-30,500
| -10% | -$358K |
|
|
B
1594
DELISTED
Barnes Group Inc.
B
| $3.09M | ﹤0.01% |
94,700
-11,000
| -10% | -$359K |
|
1595
Myriad Genetics
MYGN
$674M
| $3.09M | ﹤0.01% |
161,400
-17,900
| -10% | -$343K |
|
1596
Denison Mines
DNN
$2.12B
| $3.09M | ﹤0.01% |
1,760,700
-80,900
| -4% | -$142K |
|
1597
Levi Strauss
LEVI
$8.67B
| $3.09M | ﹤0.01% |
186,600
-21,500
| -10% | -$356K |
|
1598
Pacira BioSciences
PCRX
$1.22B
| $3.08M | ﹤0.01% |
91,400
-9,700
| -10% | -$327K |
|
1599
Oxford Industries
OXM
$701M
| $3.08M | ﹤0.01% |
30,800
-3,800
| -11% | -$380K |
|
1600
Syndax Pharmaceuticals
SNDX
$1.34B
| $3.08M | ﹤0.01% |
142,400
+21,400
| +18% | +$462K |
|